Lipoxen Share Discussion Threads

[buck581] 21/12/2010 17:36

Looks good for the long haul. If you're in for a short term profit that's fine. If you're longer term then don't let short term MM's manipulation force you out. Make your mind up and stick with it.
Merry Christmas.

[123asd] 21/12/2010 13:16

duplicate - there's also the news factor - I believe we may be about to start a period of sustained news flow, which will support the share price First in line I expect an announcement on the new NED from Baxter, as per already indicated. Following that, in H1 2011, I anticipate news of commercial hook-ups between LPX and big pharma which may aid the bottom line. All IMO etc.

[duplicate book] 21/12/2010 13:11

alphatrends........if the sell off continues over the next day or two, i'm afraid you may have to reconsider your stop!! Need buying interest to return. Nothing has changed company wise, its just market sentiment, and the fact that a lot that bought in pre news, have now moved on to the next one! Nice to see it bounce from here, but I wouldn't hold my breath.............

[alphatrends] 21/12/2010 12:58

LPX - Should bounce here, its near 12.5p support and the 20ma which is where it bounced a couple of weeks back at 10p, Ive gone long at this point with a tights stop @ 12p

[joeblogg2] 21/12/2010 12:12

Being kicked in the teeth this week with my shares and now this one :(

[bobdown2] 21/12/2010 11:31

i hope its just a tree shake..

[bobdown2] 20/12/2010 14:23

its being marked down today.........

[duplicate book] 19/12/2010 20:21

123asd.........agree with you, it is way undervalued. Makes no difference to the wider market though. Any sell off this week, or T traders closing out will see the MM's walk this back down, just as quickly as they walked it up! I'm sure you know of any number of other stocks that are way undervalued on fundementals, cash in bank, product pipeline etc? I can name one I have a shedload of, TAIH!! I would be happy to cosolidate at this level, prior to any further updates in the new year, (or this year even :o))

[123asd] 19/12/2010 19:55

Speak for yourself - this stock is way undervalued and should quadruple from this level on the strength of its portfolio of potential blockbusters.

[duplicate book] 19/12/2010 19:36

The share price has just about doubled in the space of a month. Not a bad return by anybodys standards! I will be pleased if we can stay in this 14-16p trading range for now.

[bobdown2] 17/12/2010 19:19

1p up. well maybe it deserves a post.

[buywell2] 16/12/2010 22:17

Positive Phase II Clinical Data
TIDMLPX

RNS Number : 0539Y

Lipoxen PLC

16 December 2010

16th December 2010

Lipoxen plc

('Lipoxen' or the 'Company')

Positive Phase II Clinical Data

Lipoxen (AIM: LPX.L), a bio-pharmaceutical company specialising in the development of high-value differentiated biologicals, announces that it has received positive Phase II clinical trial results for both efficacy and toxicity from the Company's long-acting erythropoietin (EPO) candidate ErepoXen. EPO is a glycoprotein hormone secreted by the kidneys that controls red blood cell production.

ErepoXen is being developed as a long acting form of EPO for the treatment of anaemia in renal disease patients. ErepoXen uses Lipoxen's proprietary PolyXen drug delivery technology which improves the efficacy stability and half life of protein drugs and reduces risk of toxicity.

Chronic kidney disease (CKD) is highly prevalent, with around 2.455 million people worldwide receiving renal replacement therapy at the end of 2009 - nearly 1.895 million on dialysis and just over 560,000 with a functioning renal transplant*. The number of people with CKD at the end of 2009 was 6 - 7% higher than at the end of 2008* and it has been forecast that this prevalence will continue to increase.

The Phase IIa trials, which consisted of 30 subjects, were carried out by the Serum Institute of India Ltd, India's largest biotech company. This was a multi-centre, randomised, open-label single, subcutaneous dose study of polysialylated erythropoietin to assess safety, pharmacodynamics and pharmacokinetics in chronic kidney disease patients not on dialysis.

Thirty subjects were enrolled into the study in three cohorts of ten subjects each. The subjects were either male between the ages of 18 or 70 or post-menopausal females under 70 years of age. The subjects were randomised to receive subcutaneous doses of either 0.5ug/kg, 1ug/kg or 2 ug/kg of polysialylated erythropoietin in the anterior femoral skin.

Dr Ashraf Mikhail, MB.Bch, MSC, MD, FRCP, MBA, Consultant Nephrologist at the Morriston Hospital and Senior Clinical Tutor at Swansea University has reviewed the study findings and has commented upon them as follows:

"The study confirms the findings of phase I trial. Polysialylated EPO is effective in increasing the reticulocyte count and thereby stimulating erythropoiesis in patients with Chronic Kidney Disease in a dose dependent manner. The rise in reticulocyte count is maintained for up to 28 days after a single injection. This finding suggests the drug may be effective when administered once monthly to patients with chronic kidney disease, thereby achieving maximal compliance and excellent outcome results". The results of the trial showed no adverse events, that the drug was well-tolerated and safe at all dose levels administered.

Lipoxen and The Serum Institute of India, as development partners in the project, will now consider the optimum development path for the commercialisation of this exitcing product candidate; this will include entering Phase II(b) trial in India as well as the possible out-licencing of the candidate to a commercial collaborator.

Commenting on the appointment, M. Scott Maguire, Chief Executive Officer of Lipoxen, said:

"I am absolutely delighted that this trial has delivered such excellent results and shown the potential for our PSA-EPO candidate to be a once-a month single dose therapy for renal disease patients. The Lipoxen Board will be working closely with our colleagues at Serum Institute to accelerate the commercialisation of this candidate. This is very exciting news indeed for Lipoxen and further underscores the viability of the PolyXen platform as a likely leading delivery methodology for a new wave of long-acting biosuperior biologic drug candidates."

* Fresenius Medical Care Annual Report 2009.

[woodcoc] 16/12/2010 20:33

so; when are we getting sulixen starting then?? Would be nice if that were in an rns in next few days..

[duplicate book] 16/12/2010 19:18

Certainly didn't expect to see us down when I got in tonight! Seems the 'buy the rumour, sell the news' brigade have been out in force today. I hope it continues its previous upward trend shortly after the dust has settled as I agree with rkhl, a discounted placing even at this price, would mean a 'problematic' dilution. (Nicely put!!)

[rkhl] 16/12/2010 15:03

The good news is that the drug delivery mechanism has proved to be effective, safe and long lasting. I can see that some people sold on the news, not a problem with profit taking, nothing moves up in a straight line. The only downside being that is has taken about an extra 5 months to finish the trial. This was the reason RHPS sold out, however, I think considering the technologies that LPX have it is a more effective method for them to get their products to market. It would have taken a lot of investors cash to get all the drugs to market they have if they had done it in-house. Still a few years to go before we know the kind of profits this company can seriously make. Possibly more good news to follow over the next few weeks however I would urge some caution as we still do not yet know how they will acquire further funding which will be necessary soon. I was hoping this would have been potentially higher (in the 20's) to avoid any problematic dilution as there will obviously be a discount on any placing. Hopefully for shareholders Scott has something up his sleeve.

[alimo] 16/12/2010 13:17

Just perhaps, the excellent news of the successful Phase2(a) is briefly reported today to be followed up with the data at a not too distant date, to milk the news to get more attention. I think your suspicions are over played,(perhaps for your own short sighted purposes, Who knows?!).

If the news was anything less than successful, the announcement would have had to draw attention to this aspect. You cannot give misinformation, surely? This is good news and there's more to come.

[ohisay] 16/12/2010 10:04

I really dont think there were any leaks as such - the epo results were promised in Q4 after the 3rd qtr delay - pi's (including me)were buying from mid Nov onwards in anticipation .

[sicilian_kan] 16/12/2010 08:08

Rubbish, show me some worded like that bobdown2.

The trial staff are always positive.

[bobdown2] 16/12/2010 08:05

lots of biotech rns/s are worded such. the important bits are the reaction of the trial staff.

[sicilian_kan] 16/12/2010 08:05

I also do not like the share price trend in the past few weeks. It makes me suspicious of leaks and I do not like leaky companies.

[123asd] 16/12/2010 07:52

sicilian - I think part of their new PR/IR outfit's brief is to make news flow less technical and more layman-friendly. That could be the reason. I don't see any reason to be suspicious.

[sicilian_kan] 16/12/2010 07:40

In fact, it is getting me angry. Why can't they state a summary of the data. They must have had it to make this RNS. It makes me suspicious that things are not as good as made out and that there may be a complication, qualification or hitch somewhere.

[sicilian_kan] 16/12/2010 07:38

There is no data. Which makes this near impossible to read.

[duplicate book] 16/12/2010 07:38

alimo.........todays RNS will surely help us head in that direction. Great News!!! Anybody more qualified and knowledgeable than me care to comment and embelish this latest update?